SWISS DAYBOOK: Lonza, Newron Pharmaceuticals, Basilea, Repower

Lonza Holding AG said it continues to expect underlying sales and earnings before interest and tax to rise this year.

The company expects solid progress based on its order pipeline, and experiences satisfactory customer demand across most markets, it said in a third-quarter trading update.

EQUITIES: *Newron Pharmaceuticals said talks with Biotie Therapies Oyj had ended, as Biotie will use its right to terminate the agreement to acquire Newron Pharmaceuticals S.p.A. and will be entitled to a break-up fee of 1.5 million euros ($2.1 million) from Newron *Basilea Pharmaceutica (BSLN) said following discussions with HBM BioVentures the company proposed Thomas Rinderknecht, Domenico Scala and Thomas Werner as additional members to the board *Repower said it may have been defrauded by IT consultants

ECONOMY: *KOF Swiss leading indicator for October at 11:30 a.m.

MARKETS: *The benchmark SMI climbed 2.2 percent to 5,823.00 *The SPI rose 2.3 percent to 5,297.06 *The Stoxx Europe 600 Index increased 3.6 percent to 249.42 *The MSCI Asia-Pacific Index rose 1.2 percent at 7:21 a.m. Zurich time *Euro-franc traded at 1.22112 at 7:22 a.m. Swiss time

To contact the reporters on this story: Elena Logutenkova in Zurich at; Carolyn Bandel in Zurich at

To contact the editor responsible for this story: Frank Connelly at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.